Description

DAONIL TAB (1X30)

Indications

Daonil Tab, containing the active ingredient glibenclamide, is primarily indicated for the management of type 2 diabetes mellitus. It is used in patients whose hyperglycemia cannot be adequately controlled with diet and exercise alone. Daonil is particularly beneficial for those who require additional glycemic control and may be used in conjunction with other antidiabetic medications.

Mechanism of Action

Glibenclamide, the active component of Daonil, belongs to the class of medications known as sulfonylureas. It functions by stimulating the pancreatic beta cells to release insulin, thereby lowering blood glucose levels. This insulin secretion is glucose-dependent, meaning that it is primarily stimulated when blood glucose levels are elevated. Additionally, glibenclamide may enhance peripheral insulin sensitivity, thereby improving glucose uptake by tissues.

Pharmacological Properties

Glibenclamide is well-absorbed from the gastrointestinal tract, with peak plasma concentrations typically occurring within 1 to 3 hours after oral administration. It has a relatively long half-life, ranging from 5 to 10 hours, which allows for once or twice-daily dosing. The drug undergoes hepatic metabolism, primarily via cytochrome P450 enzymes, and is excreted in the urine as metabolites. Its pharmacokinetic profile supports effective glycemic control in patients with type 2 diabetes.

Contraindications

Daonil Tab is contraindicated in several conditions. These include hypersensitivity to glibenclamide or any of the excipients in the formulation, type 1 diabetes mellitus, diabetic ketoacidosis, and severe renal or hepatic impairment. It should also be avoided in patients with a history of sulfonamide allergy due to the structural similarities between sulfonylureas and sulfonamide antibiotics.

Side Effects

Common side effects associated with Daonil Tab include hypoglycemia, which can manifest as dizziness, sweating, tremors, and confusion. Other potential side effects may include gastrointestinal disturbances such as nausea, vomiting, and diarrhea. Rare but serious adverse effects may include allergic reactions, liver dysfunction, and hematological disorders such as leukopenia or thrombocytopenia. Patients should be monitored regularly for these side effects, especially during the initiation of therapy.

Dosage and Administration

The recommended starting dose of Daonil Tab is typically 2.5 mg to 5 mg once daily, taken before breakfast. Depending on the patient’s blood glucose levels and tolerance, the dose may be gradually increased in increments of 2.5 mg to a maximum of 15 mg per day. It is essential for patients to adhere to the prescribed dosage and not to exceed the maximum recommended dose without medical advice. Regular monitoring of blood glucose levels is advised to ensure optimal control and to adjust the dosage as necessary.

Interactions

Daonil Tab may interact with various medications, which can either potentiate or diminish its hypoglycemic effects. Notable interactions include non-steroidal anti-inflammatory drugs (NSAIDs), certain antibiotics, and anticoagulants, which may enhance the risk of hypoglycemia. Conversely, medications such as corticosteroids, diuretics, and certain antiepileptics may reduce the effectiveness of glibenclamide. Patients should inform their healthcare provider of all medications they are taking to avoid potential drug interactions.

Precautions

Patients taking Daonil Tab should be advised to monitor their blood glucose levels regularly, especially during periods of stress, illness, or changes in diet and exercise. Caution is warranted in elderly patients and those with renal or hepatic impairment, as they may be at increased risk for adverse effects. Additionally, patients should be educated about the signs and symptoms of hypoglycemia and the appropriate management strategies. It is crucial to maintain a balanced diet and adhere to a regular exercise regimen to enhance the effectiveness of the medication.

Clinical Studies

Clinical studies have demonstrated the efficacy of glibenclamide in reducing HbA1c levels and improving overall glycemic control in patients with type 2 diabetes. In a randomized controlled trial, patients treated with glibenclamide showed significant reductions in fasting blood glucose levels compared to those receiving placebo. Furthermore, long-term studies have indicated that glibenclamide is effective in maintaining glycemic control over extended periods, with a favorable safety profile. These findings support the use of Daonil Tab as a viable option in the management of type 2 diabetes.

Conclusion

Daonil Tab is a well-established medication for the management of type 2 diabetes mellitus, offering effective glycemic control through its mechanism of action as a sulfonylurea. While it is generally well-tolerated, patients must be aware of potential side effects and drug interactions. Regular monitoring and adherence to prescribed dosages are essential for optimal treatment outcomes. As with any medication, it is crucial for patients to engage in open communication with their healthcare providers to ensure safe and effective use of Daonil Tab.